[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY34666A - Inhibidores de quinasa a base de ariléter - Google Patents

Inhibidores de quinasa a base de ariléter

Info

Publication number
UY34666A
UY34666A UY0001034666A UY34666A UY34666A UY 34666 A UY34666 A UY 34666A UY 0001034666 A UY0001034666 A UY 0001034666A UY 34666 A UY34666 A UY 34666A UY 34666 A UY34666 A UY 34666A
Authority
UY
Uruguay
Prior art keywords
ariléter
kinase inhibitors
based kinase
inhibitors
página
Prior art date
Application number
UY0001034666A
Other languages
English (en)
Inventor
Vivekananda M Vrudhula
Pan Senliang
Rajamani Ramkumar
John E Macor
Joanne J Bronson
Carolyn Diane Dzierba
Susheel Jethanand Nara
Maheswaran Sivasamban Karatholuvhu
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY34666A publication Critical patent/UY34666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se refiere en general a compuestos que pueden inhibir la AAK1 (quinasa asoc iada con el adaptador 1), composiciones que comprenden tales compuestos y métodos para inhibir la A AK1
UY0001034666A 2012-03-09 2013-03-08 Inhibidores de quinasa a base de ariléter UY34666A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261608737P 2012-03-09 2012-03-09

Publications (1)

Publication Number Publication Date
UY34666A true UY34666A (es) 2013-09-30

Family

ID=47892007

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034666A UY34666A (es) 2012-03-09 2013-03-08 Inhibidores de quinasa a base de ariléter

Country Status (11)

Country Link
US (2) US8703953B2 (es)
EP (1) EP2822952B1 (es)
JP (1) JP2015510881A (es)
CN (1) CN104144932A (es)
AR (1) AR090293A1 (es)
CA (1) CA2866671A1 (es)
EA (1) EA201491647A1 (es)
MX (1) MX2014010684A (es)
TW (1) TW201341387A (es)
UY (1) UY34666A (es)
WO (1) WO2013134036A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
CN105683196B (zh) * 2013-09-11 2018-12-21 百时美施贵宝公司 基于芳基醚的激酶抑制剂
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
EA028587B1 (ru) * 2014-01-29 2017-12-29 Бристол-Майерс Сквибб Компани Ариллактамные ингибиторы киназы
JP6441947B2 (ja) * 2014-01-31 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キノリンを基にしたキナーゼ阻害剤
MX2016012829A (es) 2014-04-02 2017-01-05 Bristol Myers Squibb Co Inhibidores de biaril cinasa.
US10174044B2 (en) 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
WO2016191245A1 (en) * 2015-05-22 2016-12-01 Dow Agrosciences Llc Recovery and/or reuse of palladium catalyst after a suzuki coupling
CN108368084B (zh) * 2015-10-01 2020-10-16 百时美施贵宝公司 联芳基激酶抑制剂
ES2767776T3 (es) * 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
CA3104116A1 (en) * 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for preparing btk inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012461A1 (en) 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
CA2477692A1 (en) 2002-04-05 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1773780A4 (en) 2004-06-24 2008-01-09 Incyte Corp AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
HUE055205T2 (hu) 2006-04-07 2021-11-29 Vertex Pharma ATP-kötõ kazetta transzporterek modulátorainak elõállítása
WO2008022155A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
CA2688299A1 (en) * 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88

Also Published As

Publication number Publication date
EP2822952A1 (en) 2015-01-14
CN104144932A (zh) 2014-11-12
TW201341387A (zh) 2013-10-16
AR090293A1 (es) 2014-11-05
US8703953B2 (en) 2014-04-22
CA2866671A1 (en) 2013-09-12
MX2014010684A (es) 2014-10-17
JP2015510881A (ja) 2015-04-13
WO2013134036A1 (en) 2013-09-12
US20140179725A1 (en) 2014-06-26
EA201491647A1 (ru) 2014-12-30
EP2822952B1 (en) 2016-04-06
US20130237555A1 (en) 2013-09-12
US8969564B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
UY34666A (es) Inhibidores de quinasa a base de ariléter
UY4211Q (es) Pizarra para marcadores
UY34654A (es) Inhibidores de la beta-secretasa
UY4276Q (es) Controlador para dispositivo electrónico
UY4169Q (es) Altoparlante
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34817A (es) Tienopirimidinas
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY33930A (es) Inhibidores novedosos de quinasas
UY4281Q (es) Juguera
UY34818A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
BR112015003294A2 (pt) caldeira de armazenamento
UY4210Q (es) Silla
UY4223Q (es) Banco
UY4153Q (es) Batería
UY4181Q (es) Taza
UY34677A (es) Imidazopiridazinas sustituidas
UY4152Q (es) Batería
UY4237Q (es) Taburete
UY34518A (es) Composiciones que contienen inhibidores de quinasas
UY34033A (es) ?nuevos inhibidores de quinasa?.
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه
CL2012003246S1 (es) Escritorio electrónico.
TN2011000162A1 (fr) نظام هندسي ومعماري مبتكر لانشاء البناء عامة ومواكب للتكنولوجيات المتطورة مادته الاساسية الطين والتربة
UY4256Q (es) ?motocicleta?.